- Conditions
- Neoplasms
- Interventions
- Gene-modified (GM) T cell therapy
- Genetic
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
Location Directory
Clinical trials in Miami, Florida
This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
12548
Shown on this page
12
Current sort
Recently updated
Location scope
Miami, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 637–648 of 12,548 matching trials in Miami, FL.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- STEMI - ST Elevation Myocardial Infarction, AMI
- Interventions
- KCCQ, Eq5D, cMRI (Subset of patients)
- Other
- Lead sponsor
- TherOx
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 27
- States / cities
- Fountain Valley, California • La Jolla, California • Laguna Hills, California + 23 more
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
- Interventions
- VENT-03, Placebo
- Drug
- Lead sponsor
- Ventus Therapeutics U.S., Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more
- Conditions
- Prostate Cancer, Hypogonadism, Male
- Interventions
- Testosterone cypionate
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
- Interventions
- Barzolvolimab, Matching Placebo
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more
- Conditions
- Primary Generalized Tonic-Clonic Seizures
- Interventions
- XEN1101, Placebo
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Frexalimab, Placebo, Insulin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
- Conditions
- Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
- Interventions
- The Supira System, Impella
- Device
- Lead sponsor
- Supira Medical
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Loma Linda, California • Sacramento, California • Thousand Oaks, California + 21 more
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 1023
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3
- Interventions
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Drug
- Lead sponsor
- Aktis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Irvine, California • Miami, Florida • Kansas City, Kansas + 5 more
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 673
- States / cities
- Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Standard of Care
- Biological · Other
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 39 more